2 Dividend Stocks to Double Up On Right Now

The article highlights Amgen and Merck as attractive dividend stocks, each yielding about 3% while navigating major patent cliffs. Amgen is benefiting from a broad product lineup, biosimilar sales, and a deep pipeline including MariTide, while Merck is diversifying beyond Keytruda with Winrevair, Capvaxive, and a subcutaneous Keytruda formulation. The piece is constructive on both companies' long-term fundamentals, but it is primarily opinion/commentary rather than new market-moving information.

Analysis

The market is treating these as simple dividend-duration names, but the real setup is a delayed-loss-replacement trade: both franchises are buying time until next-generation assets can compound through their patent cliffs. The second-order winner is not just the incumbent balance sheet; it is the capex-light biotech ecosystem around fill-finish, device components, and specialty distribution that benefits as managements prioritize execution over M&A. A key nuance is that biosimilars rarely “replace” the originator in a straight line — they fragment share, compress mix, and force a commercial response that tends to protect gross profit longer than sell-side models assume.

AMGN has the cleaner near-term path because it has more shots on goal before its current cash engine fully de-risks, but that also means the stock is more sensitive to execution slippage over the next 6-12 months. The biggest non-obvious risk is that obesity and biosimilar optionality are being capitalized too early: MariTide and Keytruda/Opdivo biosimilars are real, but any trial or regulatory delay would leave the market paying growth-multiple pricing for a stock still in transition. On the upside, if the monthly dosing profile proves differentiated, the valuation re-rating could come fast because the market will underwrite durable adherence benefits rather than just another GLP-1 entrant.

MRK is the more interesting contrarian long because consensus is already anchoring on the patent event, which usually creates an air pocket only if the replacement portfolio is weak. Here, the setup is that management can soften the cliff with formulation change, then stack multiple mid-sized assets whose combined contribution could be underappreciated until the revenue mix visibly diversifies. The key swing factor is not 2028 itself but the 12-24 months beforehand, when the market starts discounting the slope of replacement sales; if that slope inflects early, the stock can rerate well before the patent loss date.

Relative to the headline tone, the more attractive trade is to own the company with the better mix transition, not the one with the loudest pipeline narrative. In a tape that still rewards visible cash return, the dividend floor reduces downside, but the real upside comes from multiple expansion if investors begin treating these as resilient compounders rather than ex-growth pharma. The risk to that view is a broad de-risking in healthcare multiples or a sudden read-through that biosimilar pricing pressure is deeper than expected, which would hit both names simultaneously but particularly the one with less near-term pipeline proof.

Key Decisions for Investors

• Long AMGN on a 3-6 month horizon into upcoming pipeline catalysts; target 12-15% upside if MariTide and biosimilar execution remain on track, with downside limited by the dividend and diversified revenue base.
• Long MRK as a 6-12 month contrarian position ahead of the 2028 Keytruda cliff; use a staged entry on weakness, targeting a 10-14% re-rating if the market starts valuing the post-Keytruda mix transition earlier.
• Pair trade: long MRK / short a basket of single-asset large-cap pharma most exposed to one-product concentration; structure for a 6-18 month horizon where mix diversification should outperform.
• Buy AMGN or MRK calls only after confirming clinical/regulatory catalysts; avoid preloading into binary events unless using defined-risk spreads, since disappointments could compress multiples 8-12% quickly.
• For income-oriented positioning, own either name versus lower-quality yield names in healthcare; the dividend yield is not the thesis, but it provides a margin of safety while waiting for pipeline proof.